MRSA vertebral discitis managed successfully using linezolid as a component of an oral antibiotic regimen

A seventy-one-year-old female presented with one week of nausea and anorexia associated with a dry cough, breathlessness and orthopnoea. In addition she had low back pain that was severe and exacerbated by movement. Her past medical history included end-stage renal failure secondary to analgesic nephropathy and Type IV Renal Tubular Acidosis. She had been established on haemodialysis two years previously, but her fistula had clotted and was dialysed via a temporary central venous catheter. Her other co-morbidities included a stroke, a clipped cerebral aneurysm, paroxysmal ventricular tachycardia, atrial fibrillation, chronic obstructive pulmonary disease, psoriasis, gout, chronic gastritis and chronically abnormal liver function tests associated with a dilated bile duct. She required regular iron and erythropoietin infusions and had a previous severe allergic reaction to vancomycin. Nasal colonisation with MRSA had been identified six months earlier on routine surveillance cultures.

On admission she was febrile, pale, hypertensive and the site of her internal jugular dialysis catheter was erythematous with an associated purulent discharge. She was started empirically on intravenous teicoplanin for treatment of a dialysis line site infection and the dialysis line was removed. Forty-eight hours after admission, blood cultures were found to be growing staphylococci which were identified as MRSA (further identified as the epidemic strain MRSA16) which was sensitive to fusidic acid, gentamicin, rifampicin and tetracycline by disc sensitivity testing using NCCLS criteria and sensitive to linezolid (MIC = 1.5mg/L) and teicoplanin (MIC = 1.0mg/L) using E-tests (AB Biodisk, UK). Oral fusidic acid was added to the teicoplanin. In the second week of...
MRSA vertebral discitis

J R Coll Physicians Edinb 2006; 36:112–114

© 2006 RCPE

Treatment she developed a global, erythematous, itchy eruption that was diagnosed as a drug reaction due to teicoplanin and this was discontinued.

A CT scan of her thoracic spine, performed to investigate her low back pain, showed destruction of the inferior aspect of the T9 vertebral body and the superior aspect of the T10 vertebral body and discitis at this level (see Figure 1). A CT guided biopsy of the disc grew MRSA with identical antibiotic sensitivities to that isolated from blood cultures.

Treatment was commenced with oral linezolid and was well tolerated, continuing for four weeks without any adverse effect. Her CRP measurements fell on therapy as displayed in Figure 2. After four weeks of linezolid she was switched to combination therapy with oral doxycycline and oral fusidic acid because of concerns regarding the continuation of linezolid past the recommended treatment course duration of fourteen days. Fusidic acid and doxycycline were again tolerated without adverse effects and her CRP returned to the normal range.

A CT scan of the thoracic spine was repeated when antibiotic therapy stopped and showed destruction of the end plates of the T9 and T10 vertebrae with loss in vertebral height resulting from a horizontal fracture through the inferior aspect of the T9 vertebral body. These features were compatible with a recent infective discitis.

A further episode of MRSA bacteraemia with an associated raised CRP occurred seventeen weeks after finishing antibiotics and required a subsequent course of linezolid to which she responded promptly.

DISCUSSION

Vertebral discitis and osteomyelitis are recognised complications of Staphylococcus aureus bacteraemia which are more common in patients requiring renal replacement therapy,1 2 possibly due to the immunosuppressive effect of uraemia.2 Treatment with vancomycin is recommended as the first line antibiotic in haemodialysis patients for sepsis due to MRSA3 although vancomycin monotherapy has been associated with a poor outcome in the management of vertebral osteomyelitis.4 Where there is a suggestion of MRSA osteomyelitis, effective oral combination therapy should follow initial intravenous treatment with vancomycin.1 As our patient was intolerant of glycopeptides, alternative suitable antibiotic options

FIGURE 2. The response of CRP to treatment with antibiotics. The first isolate of MRSA from blood cultures was on 23/01/03. Intravenous teicoplanin (200 mg) was administered from 21/01/03 until 03/02/03 after each dialysis session. The CRP rose substantially after treatment with teicoplanin was discontinued. Linezolid was administered orally (600 mg twice daily) from 13/02/03 until 18/03/03 with a substantial fall in CRP and improvement in symptoms. Oral doxycycline (100 mg once daily) and oral fusidic acid (500 mg three times daily) were administered concurrently from 18/03/03 until 28/03/03 while the CRP returned to a normal baseline.
were limited. We are only aware of one published instance of linezolid, prescribed to treat vertebral discitis due to MRSA, and this patient had been treated initially with two weeks of intravenous vancomycin before starting linezolid.¹

Linezolid is an oxazolidinone antibiotic which is primarily excreted unchanged through the kidneys²⁻⁴ but also by a non-renal route. It inhibits the initiation of protein synthesis by binding to bacterial 23S ribosomal RNA and is active against predominantly Gram positive bacteria including multiply resistant species.⁵

Having 100% bioavailability, it is as effective when given orally as when given intravenously.⁶ Linezolid penetrates bone and can be given in renal failure.³ Around 30% of a dose is eliminated in a three hour dialysis treatment⁴ but no dose adjustments are required in dialysis patients⁵ although it has been suggested that a dose should be given immediately post-dialysis.⁷ The main adverse effects of linezolid are haematological with anaemia or, more immediately post-dialysis.⁷ The main adverse effects of linezolid are haematological with anaemia or, more commonly, thrombocytopenia occasionally developing when used for longer than fourteen days.⁶⁸ We used linezolid for four weeks without any thrombocytopenia. Although our patient required a blood transfusion during this time, her anaemia was attributed to her chronic renal failure and chronic gastritis and not the use of linezolid.

Fusidic acid is bactericidal against S. aureus, attains high serum levels and is active in pus and bone where it achieves high levels which are above the minimum inhibitory concentrations for most infections.¹⁰ There is little excretion of fusidic acid in the urine as it is mainly excreted in bile and it is 87–94 % protein bound in plasma.¹¹ It has been well established as being safe in patients requiring dialysis without requiring dose reductions,¹² although very rarely it has been cited as a cause of worsening renal function.¹³

Doxycycline, unlike other tetracyclines, is safe in renal failure. Although 30–40% is eliminated via the kidneys,¹³ its excretion is independent of renal function as increased enterohepatic metabolism can compensate for decreases in renal excretion.¹⁴ There appears to be no accumulation in plasma of doxycycline in dialysis patients.¹² Doxycycline also has the advantage of having a long plasma half-life enabling low, once-daily doses to be given. It has anti-staphylococcal activity even in many strains which are methicillin resistant and it also penetrates synovium and bone.¹³

**CONCLUSION**

We describe the successful management of MRSA vertebral discitis, which did not require surgical intervention, and was treated with an oral regimen (which was suitable for a patient who was dependent on haemodialysis) of linezolid for four weeks and then two weeks of combination therapy with fusidic acid and doxycycline.

**ACKNOWLEDGEMENTS**

We would like to thank the Scottish MRSA Reference Laboratory for the confirmatory identification and molecular typing of the MRSA isolate.

**REFERENCES**